CUDC-907: Phase I started

Curis began an open-label, dose-escalation, U.S. Phase I trial evaluating 30-180 mg oral CUDC-907 once daily in 21-day cycles in about 36 patients with relapsed or refractory lymphoma or MM. The trial...